Medline (MDLN) opened 2026 by reporting Q1 revenue of about US$7.4b and net income of US$129m, with basic EPS of US$0.16 against a trailing twelve month EPS of US$1.14 that was generated on US$29.1b of revenue and US$966m of net income. Over the past few quarters the company has seen revenue move from US$6.8b in Q4 2024 to US$6.8b in Q1 2025, then to US$7.1b in Q3 2025, US$7.8b in Q4 2025 and finally US$7.4b in Q1 2026, while quarterly basic EPS shifted from US$0.02 in Q4 2024 to US$0.02 in Q2 2025, US$0.02 in Q3 2025, US$0.22 in Q4 2025 and US$0.16 in the latest quarter. With net profit margins on a trailing basis sitting in the low single digits and trending below the prior year, the story this quarter is less about headline growth and more about how much earnings the company is keeping on each dollar of sales.

See our full analysis for Medline.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the key bullish and bearish narratives that investors have been using to frame Medline’s outlook.

Margins Under Pressure At 3.3%

• On a trailing basis, Medline converted US$29.1b of revenue into US$966m of net income, which works out to a 3.3% net margin compared with 4.7% a year earlier.
• Critics highlight that a 3.3% margin and Q1 2026 net income of US$129m leave limited room to absorb higher costs, and the data supports that concern in two ways:
  • Across the last twelve months, net income of US$966m on US$29.1b of revenue is lower margin than the prior year's 4.7% level, so profitability has tightened even though revenue has risen from US$25.5b to US$29.1b.
  • Within the recent quarters, net income moved from US$289m in Q4 2024 to US$327.5m in Q1 2025 and US$182m in Q4 2025 before US$129m in Q1 2026, which lines up with the view that earnings have been under pressure even as sales stayed in the US$6.8b to US$7.8b range.

Premium 36.8x P/E With Mixed Signals

• The stock trades on a 36.8x trailing P/E, above both the US Medical Equipment industry average of 23.6x and a peer average of 22.8x, while a DCF fair value of about US$55.29 and an analyst target of US$53.19 both sit above the current US$42.01 share price.
• What is striking for a bullish view is that valuation metrics pull in different directions, and the numbers lay out that tension clearly:
  • On one hand, a higher P/E multiple than industry and peers suggests investors are already paying up relative to similar stocks, even though trailing net margin has moved from 4.7% to 3.3%.
  • On the other hand, the current share price of US$42.01 is below both the US$53.19 analyst target and the US$55.29 DCF fair value, which aligns with forecasts that earnings could grow around 20.4% per year while revenue growth is expected at about 7.1% per year.

Curious how this mix of a premium P/E, softer margins, and upside to both DCF fair value and analyst targets fits into the wider market story for Medline, and how other investors are framing it right now, 📊 Read the what the Community is saying about Medline.

Earnings Growth Forecasts Versus Weak Interest Cover

• Forecasts point to about 20.4% yearly earnings growth compared with the broader US market at 16.1%, yet one of the key risks flagged is that interest payments are not well covered by current earnings.
• For a cautious view, the figures show why some investors focus on balance sheet strain even alongside strong growth forecasts:
  • Trailing twelve month net income of US$966m on US$29.1b of revenue and a 3.3% margin gives Medline less earnings cushion than the prior 4.7% margin period, which matters when interest coverage is already flagged as weak.
  • Quarterly net income swinging between US$333m in Q2 2025 and US$129m in Q1 2026, despite revenue holding between US$6.8b and US$7.8b, shows that profit available to service debt can vary quite a bit from one period to the next.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Medline's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mix of pressure points and potential upsides in the story so far, it is worth checking the underlying data yourself and forming a clear view. To help balance those concerns and opportunities, take a close look at the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Medline is operating on thin 3.3% margins, uneven quarterly earnings and flagged weak interest cover, which together leave little room for financial setbacks.

If those tight margins and fragile interest cover make you uneasy, you can compare that risk to companies screened for stronger financial cushions and earnings support using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.